Single Centre Prospective Evaluation of 68Gallium-FAPI PET/MRI in Hepatocellular Carcinoma

NCT05687747 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Radiolabelled tracer, 68Gallium-FAPI-46 PET/MRI

Sponsor

National University Hospital, Singapore

Collaborators

[object Object]